Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Upstream Bio, Inc. (NASDAQ: UPB) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $75.00 price target on the stock.
Upstream Bio, Inc. (NASDAQ: UPB) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $38.00 price target on the stock.
Upstream Bio, Inc. (NASDAQ: UPB) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.